<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03589976</url>
  </required_header>
  <id_info>
    <org_study_id>17-01392</org_study_id>
    <nct_id>NCT03589976</nct_id>
  </id_info>
  <brief_title>A Futility Trial of Sirolimus in Multiple System Atrophy</brief_title>
  <official_title>A Single Center Randomized,Double Blind, Placebo-controlled Futility Trial to Determine if Sirolimus is of Sufficient Promise to Slow the Progression of Multiple System Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-center, randomized, placebo-controlled, phase-II, futility clinical trial to determine&#xD;
      if oral sirolimus is of sufficient promise to slow disease progression in MSA, prior to&#xD;
      embarking on a large-scale and costly phase III study to assess its efficacy. A futility&#xD;
      design under the null hypothesis assumes that sirolimus will slow the progression of the&#xD;
      disease, whereas the alternative hypothesis assumes no benefit of sirolimus. If the null&#xD;
      hypothesis is rejected (i.e., futility of sirolimus to slow progression of MSA), a major&#xD;
      phase III study will be discouraged, whereas non-futility will offer strong support for a&#xD;
      phase III trial to detect clinical efficacy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis showed early evidence of futility of sirolimus. Trial stopped per DSMB&#xD;
    recommendation.&#xD;
  </why_stopped>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Actual">January 1, 2021</completion_date>
  <primary_completion_date type="Actual">November 20, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to 48 weeks in United Multiple System Atrophy Rating Score (UMSARS) total score in patients taking sirolimus</measure>
    <time_frame>48 Weeks</time_frame>
    <description>UMSARS is a validated, disease-specific scale representing the diverse signs and symptoms in MSA. Higher scores on the UMSARS scales mean poorer health.&#xD;
USMARS has an Activities of Daily Living score (UMSARS-1, 12 questions) that evaluates motor including autonomic activities and the Motor Examination score (UMSARS-2, 14 questions). UMSARS-3 measures supine/standing BP and UMSARS-4 is a disability scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline to 48 weeks in United Multiple System Atrophy Rating Score (UMSARS) total score in historical controls</measure>
    <time_frame>48 Weeks</time_frame>
    <description>UMSARS is a validated, disease-specific scale representing the diverse signs and symptoms in MSA. Higher scores on the UMSARS scales mean poorer health.&#xD;
USMARS has an Activities of Daily Living score (UMSARS-1, 12 questions) that evaluates motor including autonomic activities and the Motor Examination score (UMSARS-2, 14 questions). UMSARS-3 measures supine/standing BP and UMSARS-4 is a disability scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 48 weeks in United Multiple System Atrophy Rating Score (UMSARS) subscores (UMSARS-1 and UMSARS-2) in patients taking sirolimus</measure>
    <time_frame>48 Weeks</time_frame>
    <description>UMSARS-2 score (neurological examination) progression at week 48 compared to baseline; the UMSARS-1 score (activity of daily living) progression at week 48 compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 48 weeks in United Multiple System Atrophy Rating Score (UMSARS) subscores (UMSARS-1 and UMSARS-2) in historical controls</measure>
    <time_frame>48 Weeks</time_frame>
    <description>UMSARS-2 score (neurological examination) progression at week 48 compared to baseline; the UMSARS-1 score (activity of daily living) progression at week 48 compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Multiple System Atrophy</condition>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg/day (one 2-mg tablet/day). The dose of sirolimus will be adjusted throughout the trial based on sirolimus plasma levels and the presence of drug-related adverse events. The maximum dose of sirolimus will be6 mg/day (three 2-mg tablets/day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receiving placebo will undergo analog sham level measurements and the number of tablets will be also adjusted to maintain the blinding of the trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus 2 MG</intervention_name>
    <description>Dose will be adjusted trhoughout this trial based on sirolimus plasma levels and the presence of drug-related adverse events.The maximum dose will be 6mg/day.</description>
    <arm_group_label>Sirolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receiving placebo will undergo analog sham level measurements and the number of tablets will be also adjusted to maintain the blinding of the trial.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants aged 30-80 years old with a diagnosis of MSA based on clinical criteria&#xD;
             and standardized autonomic testing. This approach allows for identification of&#xD;
             patients with MSA with very high specificity and is yet sensitive enough to allow for&#xD;
             enrollment of patients at a disease stage at which an intervention on the natural&#xD;
             disease course has a meaningful impact on patient outcome. Patients therefore have to&#xD;
             fulfill current consensus criteria (1) for probable MSA of the parkinsonian subtype&#xD;
             (MSA-P) or cerebellar subtype (MSA-C) and have findings on autonomic function testing&#xD;
             suggestive of MSA.&#xD;
&#xD;
          -  Participants who are less than 4 years from the time of documented MSA diagnosis.&#xD;
&#xD;
          -  Participants who are still able to walk with or without assistance.&#xD;
&#xD;
          -  Participants with an anticipated survival of at least 3 years in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
          -  Participants who are willing and able to give informed consent.&#xD;
&#xD;
          -  Montreal Cognitive Asessment (MoCA) &gt; 20.&#xD;
&#xD;
          -  Ability to take oral medication and be willing to adhere to the study drug regimen&#xD;
&#xD;
          -  For females of reproductive potential: use of highly effective contraception for at&#xD;
             least 1 month prior to screening and agreement to use such a method during study&#xD;
             participation and for an additional 8 weeks after the end of study drug administration&#xD;
&#xD;
          -  For males of reproductive potential: use of condoms or other methods to ensure&#xD;
             effective contraception with partner&#xD;
&#xD;
          -  Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study&#xD;
             duration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of childbearing potential who do not practice an acceptable method of birth&#xD;
             control. Acceptable methods of birth control in this study are: surgical&#xD;
             sterilization, intrauterine devices, partner's vasectomy, a double-protection method&#xD;
             (condom or diaphragm with spermicide), hormonal contraceptive drug (i.e., oral&#xD;
             contraceptive, contraceptive patch, long-acting injectable contraceptive) with a&#xD;
             required second mode of contraception.&#xD;
&#xD;
          -  Participants with a clinically significant or unstable medical or surgical condition&#xD;
             that, in the opinion of the investigator, might preclude safe completion of the study&#xD;
             or might affect the results of the study. These include conditions causing significant&#xD;
             central nervous system (CNS) or autonomic dysfunction, including congestive heart&#xD;
             failure, recent (&lt;6 months) myocardial infarct, cardiopulmonary disease, severe,&#xD;
             uncontrolled hypertension, thrombocytopenia (&lt; 50 x 10(9)/L), severe anemia (&lt; 8g/dl),&#xD;
             immunocompromised state, liver or kidney disease (creatinine &gt; 1.5 mg/dl or&#xD;
             proteinuria &gt; 20 mg/dl), uncontrolled diabetes mellitus (HbA1c &gt;10g%), alcoholism,&#xD;
             amyloidosis, uncontrolled hypothyroidism, sympathectomy, unstable peripheral&#xD;
             neuropathies, concurrent infections, orthopedic problems that compromise mobility and&#xD;
             activity of daily living, cerebrovascular accidents, neurotoxin or neuroactive drug&#xD;
             exposure, parkinsonism due to drugs (including neuroleptics, alpha-methyldopa,&#xD;
             reserpine, metoclopramide).&#xD;
&#xD;
          -  Participants with high LDL cholesterol levels (LDL &gt; 160 mg/dL) and/or high&#xD;
             triglycerides levels (&gt; 200 mg/dL).&#xD;
&#xD;
          -  Participants with latent tuberculosis infection as defined as positive&#xD;
             interferon-gamma release-assay (QUANTIferonÂ®).&#xD;
&#xD;
          -  Participants with history of tuberculosis&#xD;
&#xD;
          -  Participants with a history of active, acute or chronic, or latent hepatitis B or&#xD;
             hepatitis C.&#xD;
&#xD;
          -  Participants with human immunodeficiency virus (HIV) infection, or other congenital or&#xD;
             acquired causes of immunosuppression.&#xD;
&#xD;
          -  Participants with active malignant neoplasms or history of malignant neoplasm in the&#xD;
             last 5 years.&#xD;
&#xD;
          -  Movement disorders other than MSA; e.g., Parkinson disease, dementia with Lewy bodies,&#xD;
             essential tremor, progressive supranuclear palsy, spinocerebellar ataxia, spastic&#xD;
             paraparesis, corticobasal degeneration, or vascular, pharmacological or&#xD;
             post-encephalitic parkinsonism.&#xD;
&#xD;
          -  Dementia (DSM-V criteria).&#xD;
&#xD;
          -  History of electroconvulsive therapy.&#xD;
&#xD;
          -  History of deep brain stimulation surgery.&#xD;
&#xD;
          -  Patients with contraindication for MRI scanning, including those with MRI-incompatible&#xD;
             pacemaker&#xD;
&#xD;
          -  History of organ transplant&#xD;
&#xD;
          -  Participants who have taken any investigational products within 60 days prior to&#xD;
             baseline.&#xD;
&#xD;
          -  Treatment with cyclosporine, corticosteroids, methotrexate, rituximab within 3 months&#xD;
             prior to baseline.&#xD;
&#xD;
          -  Treatment with inhibitors of CYP3A4 (which may decrease the metabolism of sirolimus&#xD;
             and increase sirolimus levels): nicardipine, verapamil, clotrimazole, fluconazole,&#xD;
             itraconazole, clarithromycin, erythromycin, troleandomycin, cisapride, metoclopramide,&#xD;
             bromocriptine, cimetidine, danazol, HIV-protease inhibitors (e.g., ritonavir,&#xD;
             indinavir); grapefruit.&#xD;
&#xD;
          -  Treatment with inducers of CYP3A4 (which may increase the metabolism of sirolimus and&#xD;
             decrease sirolimus levels): carbamazepine, phenobarbital, phenytoin, rifabutin,&#xD;
             rifapentine.&#xD;
&#xD;
          -  Inability or unwillingness of subject or legal guardian/representative to give written&#xD;
             informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose-Alberto Palma, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 5, 2018</study_first_submitted>
  <study_first_submitted_qc>July 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 5 years following article publication.</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide a methodologically sound proposal that has been approved by a local Institutional Review Board.</ipd_access_criteria>
  </patient_data>
  <pending_results>
    <submitted>November 8, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

